# Merck Moderna Melanoma Therapy Shows 42% Lower Recurrence Risk

> Merck and Moderna's melanoma combo therapy cuts recurrence risk by 42% in Phase 3 trial.
- Title: Merck Moderna Melanoma Therapy Shows 42% Lower Recurrence Risk
- Summary: Merck and Moderna's melanoma combo therapy cuts recurrence risk by 42% in Phase 3 trial. Merck and Moderna's melanoma combination therapy reduced recurrence…
- Keywords: merck, moderna, melanoma, keytruda, phase 3 trial, recurrence risk, cancer therapy, money, business, Therapy, Shows, Lower
- Source: Seekingalpha — https://seekingalpha.com/article/4957079-merck-moderna-melanoma-combination-therapy-promising-phase-3-trial-results
- Author: Derek Lowe
- Published: 2026-10-23T18:55:00+00:00
- Read time: 1 min
- Topics: merck, moderna, melanoma, keytruda, phase 3 trial, recurrence risk, cancer therapy, money, business
## Merck and Moderna Release Melanoma Trial Data
Merck and Moderna released clinical trial data on October 22, 2026 for their vaccine (intismeran autogene)/Keytruda combination in melanoma patients after surgery.
## Phase III Trial Shows 42% Lower Recurrence Risk
The Phase III data announced yesterday showed a 42% reduction in the risk of death or recurrence of melanoma after a median follow-up of two years.
## Combination Therapy Outperforms Keytruda Alone
After two years, 82.2% of the combination treatment group had not relapsed versus 70% of Keytruda-alone patients.
## Key takeaway

Merck and Moderna's melanoma combination therapy reduced recurrence or death risk by 42% after two years of follow-up in Phase 3 trial.